CHGB and pancreatic neuroendocrine tumor: Previous studies also experimentally demonstrated that an abnormal expression of CHGB was associated with aggressive VHL-associated pancreatic neuroendocrine tumors (validated by immunohistochemistry) (Weisbrod et al., 2013), pancreatic cancer (validated by qPCR) (Jia-Sheng Xu et al., 2020), and small cell lung cancer (validated by immunoblotting and qPCR) (Moss et al., 2009).